Download Eric K. Rowinsky, MD

NYULMC Home
Calendar
Site Map
Division of Hematology and Medical Oncology, New York NY | Department of Medicine
Home
About Us
Faculty
About Us
About Us
Faculty
Patient Care
Research
Education
Contact Us
Eric K. Rowinsky, MD
Eric K. Rowinsky, MD
ShareThis
Division Overview
Message from the
Division Directors
Publications
1.
Hammond-Thelin LA; Thomas MB; Iwasaki M; Abbruzzese JL; Lassere Y; Meyers CA; Hoff P; de Bono J;
Norris J; Matsushita H; Mita A; Rowinsky EK. "Phase I and pharmacokinetic study of 3'-C-ethynylcytidine
(TAS-106), an inhibitor of RNA polymerase I, II and III,in patients with advanced solid malignancies".
Investigational new drugs. 2012; 30: 316 (#144135)
Milestones
2.
3.
4.
5.
6.
7.
Rodon J; Jacobs CD; Chu Q; Rowinsky EK; Lopez-Anaya A; Takimoto CH; Wakelee HA. "A phase I
pharmacokinetic study of bexarotene with paclitaxel and carboplatin in patients with advanced non-small
cell lung cancer (NSCLC)". Cancer chemotherapy & pharmacology. 2012; 69: 825 (#144123)
Wakelee HA; Takimoto CH; Lopez-Anaya A; Chu Q; Middleton G; Dunlop D; Ramlau R; Leighl N; Rowinsky
EK; Hao D; Zatloukal P; Jacobs CD; Rodon J. "The effect of bexarotene on atorvastatin pharmacokinetics:
results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung
cancer". Cancer chemotherapy & pharmacology. 2012; 69: 563 (#144122)
Baker, J B; Dutta, D; Watson, D; Maddala, T; Munneke, B M; Shak, S; Rowinsky, E K; Xu, L-A; Harbison, C
T; Clark, E A; Mauro, D J; Khambata-Ford, S. "Tumour gene expression predicts response to cetuximab in
patients with KRAS wild-type metastatic colorectal cancer". British journal of cancer. 2011; 104: 488
(#144130)
Ko AH; Youssoufian H; Gurtler J; Dicke K; Kayaleh O; Lenz HJ; Keaton M; Katz T; Ballal S; Rowinsky EK. "A
phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as
first-line therapy for metastatic pancreatic adenocarcinoma". Investigational new drugs. 2011; 1597
(#144127)
Mita, A C; Papadopoulos, K; de Jonge, M J A; Schwartz, G; Verweij, J; Mita, M M; Ricart, A; Chu, Q S-C;
Tolcher, A W; Wood, L; McCarthy, S; Hamilton, M; Iwata, K; Wacker, B; Witt, K; Rowinsky, E K. "Erlotinib
'dosing-to-rash': a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously
treated advanced non-small cell lung cancer". British journal of cancer. 2011; 105: 938 (#144125)
Mita, Monica; Kelly, Kevin R; Mita, Alain; Ricart, Alejandro D; Romero, Ofelia; Tolcher, Anthony; Hook,
Laurel; Okereke, Chukwuemeka; Krivelevich, Ilya; Rossignol, Daniel P; Giles, Francis J; Rowinsky, Eric K;
Takimoto, Chris. "Phase I study of E7820, an oral inhibitor of integrin alpha-2 expression with
antiangiogenic properties, in patients with advanced malignancies". Clinical cancer research. 2011; 17: 193
(#144133)
8.
Pacey, Simon; Ratain, Mark J; Flaherty, Keith T; Kaye, Stanley B; Cupit, Lisa; Rowinsky, Eric K; Xia,
Chenghua; O'Dwyer, Peter J; Judson, I R. "Efficacy and safety of sorafenib in a subset of patients with
advanced soft tissue sarcoma from a Phase II randomized discontinuation trial". Investigational new drugs.
9.
Rowinsky EK; Schwartz JD; Zojwalla N; Youssoufian H; Fox F; Pultar P; Ludwig DL. "Blockade of InsulinLike Growth Factor Type-1 Receptor With Cixutumumab (IMC-A12): A Novel Approach to Treatment for
Multiple Cancers". Current drug targets. 2011; 2016 (#144126)
2011; 29: 481 (#144128)
10. Rowinsky, Eric K. "Targeting the target of rapamycin (TOR): looking to mother nature". Targeted oncology.
2011; 6: 1 (#144129)
11. Valle, Juan W; Armstrong, Anne; Newman, Chris; Alakhov, Valery; Pietrzynski, Grzegorz; Brewer, Julie;
Campbell, Sue; Corrie, Pippa; Rowinsky, Eric K; Ranson, Malcolm. "A phase 2 study of SP1049C,
doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the
esophagus and gastroesophageal junction". Investigational new drugs. 2011; 29: 1029 (#144124)
12. Wierzbicki, Rafal; Jonker, Derek J; Moore, Malcolm J; Berry, Scott R; Loehrer, Patrick J; Youssoufian,
Hagop; Rowinsky, Eric K. "A phase II, multicenter study of cetuximab monotherapy in patients with
refractory, metastatic colorectal carcinoma with absent epidermal growth factor receptor immunostaining".
Investigational new drugs. 2011; 29: 167 (#144131)
13. Zhang, W; Winder, T; Ning, Y; Pohl, A; Yang, D; Kahn, M; Lurje, G; Labonte, M J; Wilson, P M; Gordon, M
A; Hu-Lieskovan, S; Mauro, D J; Langer, C; Rowinsky, E K; Lenz, H-J. "A let-7 microRNA-binding site
polymorphism in 3'-untranslated region of KRAS gene predicts response in wild-type KRAS patients with
metastatic colorectal cancer treated with cetuximab monotherapy". Annals of oncology. 2011; 22: 104
(#144132)
14. Bonner, James A; Harari, Paul M; Giralt, Jordi; Cohen, Roger B; Jones, Christopher U; Sur, Ranjan K;
Raben, David; Baselga, Jose; Spencer, Sharon A; Zhu, Junming; Youssoufian, Hagop; Rowinsky, Eric K;
Ang, K Kian. "Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year
survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival".
Lancet oncology. 2010; 11: 21 (#144145)
15. Buckner, Jan C; Forouzesh, Bahram; Erlichman, Charles; Hidalgo, Manuel; Boni, Joseph P; Dukart, Gary;
Berkenblit, Anna; Rowinsky, Eric K. "Phase I, pharmacokinetic study of temsirolimus administered orally to
patients with advanced cancer". Investigational new drugs. 2010; 28: 334 (#144137)
16. Chu, Quincy; Mita, Alain; Forouzesh, Bahram; Tolcher, Anthony W; Schwartz, Gary; Nieto, Antonio; SotoMatos, Arturo; Alfaro, Vicente; Lebedinsky, Claudia; Rowinsky, Eric K. "Phase I and pharmacokinetic study
of sequential paclitaxel and trabectedin every 2 weeks in patients with advanced solid tumors". Clinical
cancer research. 2010; 16: 2656 (#144138)
17. Guttman-Yassky, Emma; Mita, Alain; De Jonge, Maja; Matthews, Lesley; McCarthy, Sean; Iwata, Kenneth
K; Verweij, Jaap; Rowinsky, Eric K; Krueger, James G. "Characterisation of the cutaneous pathology in nonsmall cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib". European
journal of cancer (1990). 2010; 46: 2010 (#144136)
18. Kuenen, Bart; Witteveen, Petronella O; Ruijter, Rita; Giaccone, Giuseppe; Dontabhaktuni, Aruna; Fox,
Floyd; Katz, Terry; Youssoufian, Hagop; Zhu, Junming; Rowinsky, Eric K; Voest, Emile E. "A phase I
pharmacologic study of necitumumab (IMC-11F8), a fully human IgG1 monoclonal antibody directed against
EGFR in patients with advanced solid malignancies". Clinical cancer research. 2010; 16: 1915 (#144139)
19. Schwartz, Jonathan D; Rowinsky, Eric K; Youssoufian, Hagop; Pytowski, Bronislaw; Wu, Yan. "Vascular
endothelial growth factor receptor-1 in human cancer: concise review and rationale for development of
IMC-18F1 (Human antibody targeting vascular endothelial growth factor receptor-1)". Cancer. 2010; 116:
1027 (#144140)
20. Shah, Gaurav D; Loizos, Nick; Youssoufian, Hagop; Schwartz, Jonathan D; Rowinsky, Eric K. "Rationale for
the development of IMC-3G3, a fully human immunoglobulin G subclass 1 monoclonal antibody targeting
the platelet-derived growth factor receptor alpha". Cancer. 2010; 116: 1018 (#144142)
21. Spratlin, Jennifer L; Cohen, Roger B; Eadens, Matthew; Gore, Lia; Camidge, D Ross; Diab, Sami; Leong,
Stephen; O'Bryant, Cindy; Chow, Laura Q M; Serkova, Natalie J; Meropol, Neal J; Lewis, Nancy L; Chiorean,
E Gabriela; Fox, Floyd; Youssoufian, Hagop; Rowinsky, Eric K; Eckhardt, S Gail. "Phase I pharmacologic and
biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody
targeting the vascular endothelial growth factor receptor-2". Journal of clinical oncology. 2010; 28: 780
(#144144)
22. Winder, Thomas; Zhang, Wu; Yang, Dongyun; Ning, Yan; Bohanes, Pierre; Gerger, Armin; Wilson, Peter M;
Pohl, Alexandra; Mauro, David J; Langer, Christiane; Rowinsky, Eric K; Lenz, Heinz-Josef. "Germline
polymorphisms in genes involved in the IGF1 pathway predict efficacy of cetuximab in wild-type KRAS
mCRC patients". Clinical cancer research. 2010; 16: 5591 (#144134)
23. Youssoufian, Hagop; Rowinsky, Eric K; Tonra, James; Li, Yiwen. "Targeting FMS-related tyrosine kinase
receptor 3 with the human immunoglobulin G1 monoclonal antibody IMC-EB10". Cancer. 2010; 116: 1013
(#144141)
24. Zhong, Zhaojing; Carroll, Kyla Driscoll; Policarpio, Desiree; Osborn, Carla; Gregory, Michael; Bassi, Rajiv;
Jimenez, Xenia; Prewett, Marie; Liebisch, Gregory; Persaud, Kris; Burtrum, Douglas; Wang, Su;
Surguladze, David; Ng, Stanley; Griffith, Heather; Balderes, Paul; Doody, Jacqueline; Schwartz, Jonathan
D; Youssoufian, Hagop; Rowinsky, Eric K; Ludwig, Dale L; Witte, Larry; Zhu, Zhenping; Wu, Yan. "Antitransforming growth factor beta receptor II antibody has therapeutic efficacy against primary tumor growth
and metastasis through multieffects on cancer, stroma, and immune cells". Clinical cancer research. 2010;
16: 1191 (#144143)
25. Forouzesh, Bahram; Hidalgo, Manuel; Chu, Quincy; Mita, Alain; Mita, Monica; Schwartz, Garry; Jimeno,
Jose; Gomez, Javier; Alfaro, Vicente; Lebedinsky, Claudia; Zintl, Patrik; Rowinsky, Eric K. "Phase I and
pharmacokinetic study of trabectedin as a 1- or 3-hour infusion weekly in patients with advanced solid
malignancies". Clinical cancer research. 2009; 15: 3591 (#144149)
26. Goel, Sanjay; Mita, Alain C; Mita, Monica; Rowinsky, Eric K; Chu, Quincy S; Wong, Nancy; Desjardins,
Christopher; Fang, Fang; Jansen, Mendel; Shuster, Dale E; Mani, Sridhar; Takimoto, Chris H. "A phase I
study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients
with advanced solid malignancies". Clinical cancer research. 2009; 15: 4207 (#144148)
27. Lin, Chia-Chi; Beeram, Muralidhar; Rowinsky, Eric K; Takimoto, Chris H; Ng, Chee M; Geyer, Charles E Jr;
Denis, Louis J; De Bono, Johann S; Hao, Desiree; Tolcher, Anthony W; Rha, Sun-Young; Jolivet, Jacques;
Patnaik, Amita. "Phase I and pharmacokinetic study of cisplatin and troxacitabine administered
intravenously every 28 days in patients with advanced solid malignancies". Cancer chemotherapy &
pharmacology. 2009; 65: 167 (#144146)
28. Lockhart, A Craig; Calvo, Emiliano; Tolcher, Anthony W; Rowinsky, Eric K; Shackleton, Gareth; Morrison, J
Gilmour; Rafi, Rezvan; VerMeulen, Wendy; Rothenberg, Mace L. "A phase I dose-escalation study of
SR271425, an intravenously dosed thioxanthone analog, administered weekly in patients with refractory
solid tumors". American journal of clinical oncology. 2009; 32: 9 (#144150)
29. Mita, Alain C; Denis, Louis J; Rowinsky, Eric K; Debono, Johann S; Goetz, Andrew D; Ochoa, Leonel;
Forouzesh, Bahram; Beeram, Muralidhar; Patnaik, Amita; Molpus, Kathleen; Semiond, Dorothee; Besenval,
Michele; Tolcher, Anthony W. "Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel
taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors". Clinical
cancer research. 2009; 15: 723 (#144151)
30. Mita, Monica; Mita, Alain; Sarantopoulos, John; Takimoto, Chris H; Rowinsky, Eric K; Romero, Ofelia;
Angiuli, Patrizia; Allievi, Cecilia; Eisenfeld, Amy; Verschraegen, Claire F. "Phase I study of paclitaxel
poliglumex administered weekly for patients with advanced solid malignancies". Cancer chemotherapy &
pharmacology. 2009; 64: 287 (#144147)
31. Baker, Laurence H; Rowinsky, Eric K; Mendelson, David; Humerickhouse, Rod A; Knight, Raymond A; Qian,
Jiang; Carr, Robert A; Gordon, Gary B; Demetri, George D. "Randomized, phase II study of the
thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced soft tissue sarcoma".
Journal of clinical oncology. 2008; 26: 5583 (#144154)
32. Chu, Quincy S C; Cianfrocca, Mary E; Goldstein, Lori J; Gale, Meg; Murray, Nicholas; Loftiss, Jill; Arya,
Nikita; Koch, Kevin M; Pandite, Lini; Fleming, Ronald A; Paul, Elaine; Rowinsky, Eric K. "A phase I and
pharmacokinetic study of lapatinib in combination with letrozole in patients with advanced cancer". Clinical
cancer research. 2008; 14: 4484 (#144156)
33. de Bono, Johann S; Kristeleit, Rebecca; Tolcher, Anthony; Fong, Peter; Pacey, Simon; Karavasilis, Vasilios;
Mita, Monica; Shaw, Heather; Workman, Paul; Kaye, Stan; Rowinsky, Eric K; Aherne, Wynne; Atadja,
Peter; Scott, Jeffrey W; Patnaik, Amita. "Phase I pharmacokinetic and pharmacodynamic study of LAQ824,
a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with
advanced solid tumors". Clinical cancer research. 2008; 14: 6663 (#144155)
34. Lurje, Georg; Nagashima, Fumio; Zhang, Wu; Yang, Dongyun; Chang, Heung M; Gordon, Michael A; El-
35.
36.
37.
38.
39.
Khoueiry, Anthony; Husain, Hatim; Wilson, Peter M; Ladner, Robert D; Mauro, David J; Langer, Christiane;
Rowinsky, Eric K; Lenz, Heinz-Josef. "Polymorphisms in cyclooxygenase-2 and epidermal growth factor
receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer
patients treated with single-agent cetuximab". Clinical cancer research. 2008; 14: 7884 (#144153)
Mita, Monica M; Mita, Alain C; Chu, Quincy S; Rowinsky, Eric K; Fetterly, Gerald J; Goldston, Michelle;
Patnaik, Amita; Mathews, Lesley; Ricart, Alejandro D; Mays, Theresa; Knowles, Heather; Rivera, Victor M;
Kreisberg, Jeff; Bedrosian, Camille L; Tolcher, Anthony W. "Phase I trial of the novel mammalian target of
rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2
weeks to patients with advanced malignancies". Journal of clinical oncology. 2008; 26: 361 (#144157)
Ricart, Alejandro D; Berlin, Jordan D; Papadopoulos, Kyriakos P; Syed, Samira; Drolet, Daniel W;
Quaratino-Baker, Charlotte; Horan, Julie; Chick, Jon; Vermeulen, Wendy; Tolcher, Anthony W; Rowinsky,
Eric K; Rothenberg, Mace L. "Phase I, pharmacokinetic and biological correlative study of OSI-7904L, a
novel liposomal thymidylate synthase inhibitor, and cisplatin in patients with solid tumors". Clinical cancer
research. 2008; 14: 7947 (#144152)
Calvo, E; Malik, S N; Siu, L L; Baillargeon, G M; Irish, J; Chin, S F; Santabarbara, P; Kreisberg, J I;
Rowinsky, E K; Hidalgo, M. "Assessment of erlotinib pharmacodynamics in tumors and skin of patients with
head and neck cancer". Annals of oncology. 2007; 18: 761 (#144168)
Chu, Quincy S C; Forouzesh, Bahram; Syed, Samira; Mita, Monica; Schwartz, Garry; Cooper, Joshua;
Curtright, Janet; Rowinsky, Eric K. "A phase II and pharmacological study of the matrix metalloproteinase
inhibitor (MMPI) COL-3 in patients with advanced soft tissue sarcomas". Investigational new drugs. 2007;
25: 359 (#144162)
Chu, Quincy S C; Schwartz, Garry; de Bono, Johann; Smith, Deborah A; Koch, Kevin M; Versola, Melissa J;
Pandite, Lini; Arya, Nikita; Curtright, Jan; Fleming, Ronald A; Ho, Peter T C; Rowinsky, Eric K. "Phase I and
pharmacokinetic study of lapatinib in combination with capecitabine in patients with advanced solid
malignancies". Journal of clinical oncology. 2007; 25: 3753 (#144161)
40. Curran, Desmond; Giralt, Jordi; Harari, Paul M; Ang, K Kian; Cohen, Roger B; Kies, Merrill S; Jassem,
Jacek; Baselga, Jose; Rowinsky, Eric K; Amellal, Nadia; Comte, Sylvie; Bonner, James A. "Quality of life in
head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with
cetuximab". Journal of clinical oncology. 2007; 25: 2191 (#144165)
41. Dragovich, Tomislav; Huberman, Mark; Von Hoff, Daniel D; Rowinsky, Eric K; Nadler, Paul; Wood, Debra;
Hamilton, Marta; Hage, George; Wolf, Julie; Patnaik, Amita. "Erlotinib plus gemcitabine in patients with
unresectable pancreatic cancer and other solid tumors: phase IB trial". Cancer chemotherapy &
pharmacology. 2007; 60: 295 (#144163)
42. Mita, Alain C; Olszanski, Anthony J; Walovitch, Richard C; Perez, Raymond P; MacKay, Kathleen; Tuck,
David P; Simmons, Cecilia; Hammond, Susan; Mita, Monica M; Beeram, Muralidhar; Stone, Anne J;
Rowinsky, Eric K; Lewis, Lionel D. "Phase I and pharmacokinetic study of AI-850, a novel microparticle
hydrophobic drug delivery system for paclitaxel". Clinical cancer research. 2007; 13: 3293 (#144164)
43. Mita, Monica M; Rowinsky, Eric K; Forero, Leonardo; Eckhart, S Gail; Izbicka, Elzbieta; Weiss, Geoffrey R;
Beeram, Muralidhar; Mita, Alain C; de Bono, Johann S; Tolcher, Anthony W; Hammond, Lisa A; Simmons,
Paul; Berg, Kristin; Takimoto, Chris; Patnaik, Amita. "A phase II, pharmacokinetic, and biologic study of
semaxanib and thalidomide in patients with metastatic melanoma". Cancer chemotherapy & pharmacology.
2007; 59: 165 (#144169)
44. Rowinsky, Eric K; Beeram, Muralidhar; Hammond, Lisa A; Schwartz, Garry; De Bono, Johann; Forouzesh,
Baharam; Chu, Quincy; Latz, Jane E; Hong, Shengyan; John, William; Nguyen, Binh. "A phase I and
pharmacokinetic study of pemetrexed plus irinotecan in patients with advanced solid malignancies". Clinical
cancer research. 2007; 13: 532 (#144170)
45. Rowinsky, Eric K; Youssoufian, Hagop; Tonra, James R; Solomon, Phillip; Burtrum, Douglas; Ludwig, Dale L.
"IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor". Clinical cancer
research. 2007; 13: 5549s (#144159)
46. Sparreboom, Alex; Wolff, Antonio C; Mathijssen, Ron H J; Chatelut, Etienne; Rowinsky, Eric K; Verweij,
Jaap; Baker, Sharyn D. "Evaluation of alternate size descriptors for dose calculation of anticancer drugs in
the obese". Journal of clinical oncology. 2007; 25: 4707 (#144158)
47. Takimoto, Chris H; Hammond-Thelin, Lisa A; Latz, Jane E; Forero, Leonardo; Beeram, Muralidhar;
Forouzesh, Bahram; de Bono, Johann; Tolcher, Anthony W; Patnaik, Amita; Monroe, Pamela; Wood, Leslie;
Schneck, Karen B; Clark, Romnee; Rowinsky, Eric K. "Phase I and pharmacokinetic study of pemetrexed
with high-dose folic acid supplementation or multivitamin supplementation in patients with locally advanced
or metastatic cancer". Clinical cancer research. 2007; 13: 2675 (#144166)
48. Youssoufian, Hagop; Hicklin, Daniel J; Rowinsky, Eric K. "Review: monoclonal antibodies to the vascular
endothelial growth factor receptor-2 in cancer therapy". Clinical cancer research. 2007; 13: 5544s
(#144160)
49. Youssoufian, Hagop; Rowinsky, Eric K. "A remedy for biomarker addiction: back to rational anticancer drug
development". Nature clinical practice. Oncology. 2007; 4: 264 (#144167)
50. Bonner, James A; Harari, Paul M; Giralt, Jordi; Azarnia, Nozar; Shin, Dong M; Cohen, Roger B; Jones,
Christopher U; Sur, Ranjan; Raben, David; Jassem, Jacek; Ove, Roger; Kies, Merrill S; Baselga, Jose;
Youssoufian, Hagop; Amellal, Nadia; Rowinsky, Eric K; Ang, K Kian. "Radiotherapy plus cetuximab for
squamous-cell carcinoma of the head and neck". New England journal of medicine. 2006; 354: 567
(#144180)
51. Erlichman, Charles; Hidalgo, Manuel; Boni, Joseph P; Martins, Patricia; Quinn, Susan E; Zacharchuk,
Charles; Amorusi, Peter; Adjei, Alex A; Rowinsky, Eric K. "Phase I study of EKB-569, an irreversible
inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors". Journal of clinical
oncology. 2006; 24: 2252 (#144177)
52. Hidalgo, Manuel; Buckner, Jan C; Erlichman, Charles; Pollack, Marilyn S; Boni, Joseph P; Dukart, Gary;
Marshall, Bonnie; Speicher, Lisa; Moore, Laurence; Rowinsky, Eric K. "A phase I and pharmacokinetic study
of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with
advanced cancer". Clinical cancer research. 2006; 12: 5755 (#144173)
53. Lee, Carlton K K; Rowinsky, Eric K; Li, Jing; Giles, Francis; Moore, Malcolm J; Hidalgo, Manuel; Capparelli,
Edmund; Jolivet, Jacques; Baker, Sharyn D. "Population pharmacokinetics of troxacitabine, a novel
dioxolane nucleoside analogue". Clinical cancer research. 2006; 12: 2158 (#144179)
54. Lenz, Heinz-Josef; Van Cutsem, Eric; Khambata-Ford, Shirin; Mayer, Robert J; Gold, Philip; Stella, Philip;
Mirtsching, Barry; Cohn, Allen L; Pippas, Andrew W; Azarnia, Nozar; Tsuchihashi, Zenta; Mauro, David J;
Rowinsky, Eric K. "Multicenter phase II and translational study of cetuximab in metastatic colorectal
carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines". Journal of clinical oncology. 2006;
24: 4914 (#144172)
55. Mita, Alain C; Hammond, Lisa A; Bonate, Peter L; Weiss, Geoffrey; McCreery, Heather; Syed, Samira;
Garrison, Mitchell; Chu, Quincy S C; DeBono, Johann S; Jones, Christopher B; Weitman, Steve; Rowinsky,
Eric K. "Phase I and pharmacokinetic study of tasidotin hydrochloride (ILX651), a third-generation
dolastatin-15 analogue, administered weekly for 3 weeks every 28 days in patients with advanced solid
tumors". Clinical cancer research. 2006; 12: 5207 (#144174)
56. Mita, Alain C; Sweeney, Christopher J; Baker, Sharyn D; Goetz, Andrew; Hammond, Lisa A; Patnaik, Amita;
Tolcher, Anthony W; Villalona-Calero, Miguel; Sandler, Alan; Chaudhuri, Tuhin; Molpus, Kathleen; Latz,
Jane E; Simms, Lorinda; Chaudhary, Ajai K; Johnson, Robert D; Rowinsky, Eric K; Takimoto, Chris H.
"Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer
patients with normal and impaired renal function". Journal of clinical oncology. 2006; 24: 552 (#144182)
57. Mita, M M; Ochoa, L; Rowinsky, E K; Kuhn, J; Schwartz, G; Hammond, L A; Patnaik, A; Yeh, I-T; Izbicka,
E; Berg, K; Tolcher, A W. "A phase I, pharmacokinetic and biologic correlative study of oblimersen sodium
(Genasense, G3139) and irinotecan in patients with metastatic colorectal cancer". Annals of oncology.
2006; 17: 313 (#144181)
58. Patnaik, Amita; Wood, Debra; Tolcher, Anthony W; Hamilton, Marta; Kreisberg, Jeffrey I; Hammond, Lisa
A; Schwartz, Garry; Beeram, Muralidhar; Hidalgo, Manuel; Mita, Monica M; Wolf, Julie; Nadler, Paul;
Rowinsky, Eric K. "Phase I, pharmacokinetic, and biological study of erlotinib in combination with paclitaxel
and carboplatin in patients with advanced solid tumors". Clinical cancer research. 2006; 12: 7406
(#144171)
59. Rowinsky, Eric K. "Lately, it occurs to me what a long, strange trip it's been for the farnesyltransferase
inhibitors". Journal of clinical oncology. 2006; 24: 2981 (#144176)
60. Rowinsky, Eric K; Calvo, Emiliano. "Novel agents that target tublin and related elements". Seminars in
oncology. 2006; 33: 421 (#144175)
61. Sweeney, Christopher J; Takimoto, Chris H; Latz, Jane E; Baker, Sharyn D; Murry, Daryl J; Krull, James H;
Fife, Karen; Battiato, Linda; Cleverly, Ann; Chaudhary, Ajai K; Chaudhuri, Tuhin; Sandler, Alan; Mita, Alain
C; Rowinsky, Eric K. "Two drug interaction studies evaluating the pharmacokinetics and toxicity of
pemetrexed when coadministered with aspirin or Ibuprofen in patients with advanced cancer". Clinical
cancer research. 2006; 12: 536 (#144183)
62. Tolcher, Anthony W; Hao, Desiree; de Bono, Johann; Miller, Alex; Patnaik, Amita; Hammond, Lisa A;
Smetzer, Leslie; Van Wart Hood, Jill; Merritt, James; Rowinsky, Eric K; Takimoto, Chris; Von Hoff, Dan;
Eckhardt, S Gail. "Phase I, pharmacokinetic, and pharmacodynamic study of intravenously administered
Ad5CMV-p53, an adenoviral vector containing the wild-type p53 gene, in patients with advanced cancer".
Journal of clinical oncology. 2006; 24: 2052 (#144178)
63. Abou-Alfa, Ghassan K; Rowinsky, Eric K; Patt, Yehuda Z; Schwartz, Gary K; Kelsen, David P; Sharma,
Sunil; Siegel, Eve; Becerra, Carlos R; Eckhardt, S Gail; Feit, Kevie; De Jager, Robert; O'Reilly, Eileen M. "A
Phase II study of intravenous exatecan administered daily for 5 days, every 3 weeks to patients with biliary
tract cancers". American journal of clinical oncology. 2005; 28: 334 (#144189)
64. Beeram, Muralidhar; Patnaik, Amita; Rowinsky, Eric K. "Raf: a strategic target for therapeutic development
against cancer". Journal of clinical oncology. 2005; 23: 6771 (#144188)
65. Calvo, Emiliano; Rowinsky, Eric K. "Approaches to optimize the use of monoclonal antibodies to epidermal
growth factor receptor". Current oncology reports. 2005; 7: 123 (#144190)
66. Calvo, Emiliano; Rowinsky, Eric K. "Clinical experience with monoclonal antibodies to epidermal growth
factor receptor". Current oncology reports. 2005; 7: 96 (#144191)
67. Posey, James A 3rd; Saif, M Wasif; Carlisle, Ronda; Goetz, Andrew; Rizzo, Jinee; Stevenson, Suzanne;
Rudoltz, Marc S; Kwiatek, Joseph; Simmons, Paul; Rowinsky, Eric K; Takimoto, Chris H; Tolcher, Anthony
W. "Phase 1 study of weekly polyethylene glycol-camptothecin in patients with advanced solid tumors and
lymphomas". Clinical cancer research. 2005; 11: 7866 (#144186)
68. Ricart, Alejandro D; Hammond, Lisa A; Kuhn, John G; Takimoto, Chris H; Goetz, Andrew; Forouzesh,
Bahram; Forero, Leonardo; Ochoa-Bayona, Jose L; Berg, Kristin; Tolcher, Anthony W; Rowinsky, Eric K.
"Phase I and pharmacokinetic study of sequences of the rebeccamycin analogue NSC 655649 and cisplatin
in patients with advanced solid tumors". Clinical cancer research. 2005; 11: 8728 (#144185)
69. Rowinsky, Eric K. "Erosion of the principal investigator role in a climate of industry dominance". European
journal of cancer (1990). 2005; 41: 2206 (#144187)
70. Rowinsky, Eric K. "Targeted induction of apoptosis in cancer management: the emerging role of tumor
necrosis factor-related apoptosis-inducing ligand receptor activating agents". Journal of clinical oncology.
2005; 23: 9394 (#144184)
71. Calvo, Emiliano; Rowinsky, Eric K. "Effect of epidermal growth factor receptor mutations on the response to
epidermal growth factor receptor tyrosine kinase inhibitors: target-based populations for target-based
drugs". Clinical lung cancer. 2004; 6 Suppl 1: S35 (#144193)
72. Calvo, Emiliano; Tolcher, Anthony W; Hammond, Lisa A; Patnaik, Amita; de Bono, Johan S; Eiseman, Irene
A; Olson, Stephen C; Lenehan, Peter F; McCreery, Heather; Lorusso, Patricia; Rowinsky, Eric K.
"Administration of CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, is feasible on a 7-day on, 7day off schedule: a phase I pharmacokinetic and food effect study". Clinical cancer research. 2004; 10:
7112 (#144195)
73. Chu, Quincy Siu-Chung; Hammond, Lisa A; Schwartz, Garry; Ochoa, Leonel; Rha, Sun-Young; Denis,
Louis; Molpus, Kathleen; Roedig, Brian; Letrent, Stephen P; Damle, Bharat; DeCillis, Arthur P; Rowinsky,
Eric K. "Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day
schedule in patients with advanced malignancies". Clinical cancer research. 2004; 10: 4913 (#144200)
74. de Bono, J S; Rha, S Y; Stephenson, J; Schultes, B C; Monroe, P; Eckhardt, G S; Hammond, L A;
Whiteside, T L; Nicodemus, C F; Cermak, J M; Rowinsky, E K; Tolcher, A W. "Phase I trial of a murine
antibody to MUC1 in patients with metastatic cancer: evidence for the activation of humoral and cellular
antitumor immunity". Annals of oncology. 2004; 15: 1825 (#144192)
75. de Bono, Johann S; Tolcher, Anthony W; Forero, Andre; Vanhove, Gertrude F A; Takimoto, Chris; Bauer,
Robert J; Hammond, Lisa A; Patnaik, Amita; White, Mark L; Shen, Sui; Khazaeli, Muhammad B; Rowinsky,
Eric K; LoBuglio, Albert F. "ING-1, a monoclonal antibody targeting Ep-CAM in patients with advanced
adenocarcinomas". Clinical cancer research. 2004; 10: 7555 (#144194)
76. Foon, Kenneth A; Yang, Xiao-Dong; Weiner, Louis M; Belldegrun, Arie S; Figlin, Robert A; Crawford,
Jeffrey; Rowinsky, Eric K; Dutcher, Janice P; Vogelzang, Nicholas J; Gollub, Jared; Thompson, John A;
Schwartz, Garry; Bukowski, Ronald M; Roskos, Lorin K; Schwab, Gisela M. "Preclinical and clinical
evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody". International
journal of radiation oncology biology physics. 2004; 58: 984 (#144208)
77. Hammond, Lisa A; Eckardt, John R; Kuhn, John G; Gerson, Stanton L; Johnson, Tom; Smith, Lon; Drengler,
Ronald L; Campbell, Elizabeth; Weiss, Geoffrey R; Von Hoff, Daniel D; Rowinsky, Eric K. "A randomized
phase I and pharmacological trial of sequences of 1,3-bis(2-chloroethyl)-1-nitrosourea and temozolomide
in patients with advanced solid neoplasms". Clinical cancer research. 2004; 10: 1645 (#144207)
78. Lynch, Thomas J; Adjei, Alex A; Bunn, Paul A Jr; DuBois, Raymond N; Gandara, David R; Giaccone,
Giuseppe; Govindan, Ramaswamy; Herbst, Roy S; Johnson, Bruce E; Khuri, Fadlo R; Perez-Soler, Roman;
Rosell, Rafael; Rowinsky, Eric K; Sandler, Alan B; Scagliotti, Giorgio V; Schiller, Joan H; Shapiro, Geoffrey
I; Socinski, Mark A; Hart, Carol S. "Novel agents in the treatment of lung cancer: conference summary
statement". Clinical cancer research. 2004; 10: 4199s (#144204)
79. Melendez, Robert F; Harrison, Joseph M; Rowinsky, Eric K; Hammond, Lisa A; Fitzsimmons, Thomas D.
"Acute retinal toxicity from the novel anti-tumor agent, Irofulven". Documenta ophthalmologica. 2004; 108:
249 (#144205)
80. Mita, Alain C; Mita, Monica M; Rowinsky, Eric K. "Development of rationally designed, target-based agents
for the treatment of advanced colorectal cancer". Clinical colorectal cancer. 2004; 4: 107 (#144202)
81. Perez-Soler, Roman; Chachoua, Abraham; Hammond, Lisa A; Rowinsky, Eric K; Huberman, Mark; Karp,
Daniel; Rigas, James; Clark, Gary M; Santabarbara, Pedro; Bonomi, Philip. "Determinants of tumor
response and survival with erlotinib in patients with non--small-cell lung cancer". Journal of clinical
oncology. 2004; 22: 3238 (#44862)
82. Rowinsky, Eric K. "A widening prospect: Imatinib and novel applications of targeted therapy". Seminars in
oncology. 2004; 31: 1 (#144206)
83. Rowinsky, Eric K. "Curtailing the high rate of late-stage attrition of investigational therapeutics against
unprecedented targets in patients with lung and other malignancies". Clinical cancer research. 2004; 10:
4220s (#144203)
84. Rowinsky, Eric K. "Targeting the molecular target of rapamycin (mTOR)". Current opinion in oncology.
2004; 16: 564 (#144196)
85. Rowinsky, Eric K. "The erbB family: targets for therapeutic development against cancer and therapeutic
strategies using monoclonal antibodies and tyrosine kinase inhibitors". Annual review of medicine. 2004;
55: 433 (#144209)
86. Rowinsky, Eric K; Schwartz, Garry H; Gollob, Jared A; Thompson, John A; Vogelzang, Nicholas J; Figlin,
Robert; Bukowski, Ronald; Haas, Naomi; Lockbaum, Pamela; Li, Yu-Ping; Arends, Rosalin; Foon, Kenneth
A; Schwab, Gisela; Dutcher, Janice. "Safety, pharmacokinetics, and activity of ABX-EGF, a fully human antiepidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer". Journal
of clinical oncology. 2004; 22: 3003 (#144201)
87. Royce, Melanie E; Rowinsky, Eric K; Hoff, Paulo M; Coyle, John; DeJager, Robert; Pazdur, Richard; Saltz,
Leonard B. "A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for five days
every three weeks to patients with metastatic adenocarcinoma of the colon or rectum". Investigational new
drugs. 2004; 22: 53 (#144210)
88. Schwartz, Garry H; Jones, Christopher B; Garrison, Mitchell; Patnaik, Amita; Takimoto, Chris; McCreery,
Heather; Skinner, Michael; Tolcher, Anthony W; Rowinsky, Eric K. "A phase I and pharmacokinetic study of
the nonpolyglutamatable thymidylate synthase inhibitor ZD9331 plus docetaxel in patients with advanced
solid malignancies". Investigational new drugs. 2004; 22: 437 (#144197)
89. Syed, Samira; Takimoto, Chris; Hidalgo, Manuel; Rizzo, Jinee; Kuhn, John G; Hammond, Lisa A; Schwartz,
Garry; Tolcher, Anthony; Patnaik, Amita; Eckhardt, S Gail; Rowinsky, Eric K. "A phase I and
pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix
metalloproteinase and antitumor properties". Clinical cancer research. 2004; 10: 6512 (#144198)
90. Tolcher, Anthony W; Kuhn, John; Schwartz, Garry; Patnaik, Amita; Hammond, Lisa A; Thompson, Ian;
Fingert, Howard; Bushnell, David; Malik, Shazli; Kreisberg, Jeffrey; Izbicka, Elzbieta; Smetzer, Leslie;
Rowinsky, Eric K. "A Phase I pharmacokinetic and biological correlative study of oblimersen sodium
(genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with
hormone-refractory prostate cancer". Clinical cancer research. 2004; 10: 5048 (#144199)
91. Adjei, Alex A; Rowinsky, Eric K. "Novel anticancer agents in clinical development". Cancer biology &
therapy. 2003; 2: S5 (#144218)
92. Beeram, Muralidhar; Patnaik, Amita; Rowinsky, Erick K. "Regulation of c-Raf-1: therapeutic implications".
Clinical advances in hematology & oncology : H&O. 2003; 1: 476 (#144214)
93. Budman, Daniel; Calvert, A. Hilary; Rowinsky, Eric K. "Handbook of anticancer drug development". 2003;
(#2111)
94. Cannistra, Stephen A; Bast, Robert C Jr; Berek, Jonathan S; Bookman, Michael A; Crum, Christopher P;
DePriest, Paul D; Garber, Judy E; Koh, Wui-Jin; Markman, Maurie; McGuire, William P 3rd; Rose, Peter G;
Rowinsky, Eric K; Rustin, Gordon J S; Skates, Steven J; Vasey, Paul A; King, Laura. "Progress in the
management of gynecologic cancer: consensus summary statement". Journal of clinical oncology. 2003;
21: 129s (#144224)
95. de Bono, Johann S; Tolcher, Anthony W; Rowinsky, Eric K. "Farnesyltransferase inhibitors and their
potential in the treatment of breast carcinoma". Seminars in oncology. 2003; 30: 79 (#144213)
96. de Bono, Johann S; Tolcher, Anthony W; Rowinsky, Eric K. "The future of cytotoxic therapy: selective
cytotoxicity based on biology is the key". Breast cancer research. 2003; 5: 154 (#144231)
97. Dees, E Claire; Rowinsky, Eric K; Noe, Dennis A; O'Reilly, Seamus; Adjei, Alex A; Elza-Brown, Kathy;
Donehower, Ross C. "A phase I and pharmacologic study of pyrazoloacridine and cisplatin in patients with
advanced cancer". Investigational new drugs. 2003; 21: 75 (#144229)
98. Forouzesh, Bahram; Takimoto, Chris H; Goetz, Andrew; Diab, Sami; Hammond, Lisa A; Smetzer, Leslie;
Schwartz, Garry; Gazak, Robert; Callaghan, John T; Von Hoff, Daniel D; Rowinsky, Eric K. "A phase I and
pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week
schedule in patients with advanced solid malignancies". Clinical cancer research. 2003; 9: 5540 (#144211)
99. Garrison, Mitchell A; Hammond, Lisa A; Geyer, Charles E Jr; Schwartz, Garry; Tolcher, Anthony W;
Smetzer, Leslie; Figueroa, Jose A; Ducharme, Murray; Coyle, John; Takimoto, Chris H; De Jager, Robert L;
Rowinsky, Eric K. "A Phase I and pharmocokinetic study of exatecan mesylate administered as a protracted
21-day infusion in patients with advanced solid malignancies". Clinical cancer research. 2003; 9: 2527
(#144219)
100.Hao, Desiree; Hammond, Lisa A; Eckhardt, S Gail; Patnaik, Amita; Takimoto, Chris H; Schwartz, Garry H;
Goetz, Andrew D; Tolcher, Anthony W; McCreery, Heather A; Mamun, Khalid; Williams, Jon I; Holroyd,
Kenneth J; Rowinsky, Eric K. "A Phase I and pharmacokinetic study of squalamine, an aminosterol
angiogenesis inhibitor". Clinical cancer research. 2003; 9: 2465 (#144221)
101.Malik, Shazli N; Siu, Lillian L; Rowinsky, Eric K; deGraffenried, Linda; Hammond, Lisa A; Rizzo, Jinee;
Bacus, Sarah; Brattain, Michael G; Kreisberg, Jeffrey I; Hidalgo, Manuel. "Pharmacodynamic evaluation of
the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients". Clinical
cancer research. 2003; 9: 2478 (#144220)
102.Meropol, Neal J; Somer, Robert A; Gutheil, John; Pelley, Robert J; Modiano, Manuel R; Rowinsky, Eric K;
Rothenberg, Mace L; Redding, Spencer W; Serdar, Cuneyt M; Yao, Bin; Heard, Robert; Rosen, Lee S.
"Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential
role as mucosal protectant". Journal of clinical oncology. 2003; 21: 1452 (#144226)
103.Mita, Monica M; Mita, Alain; Rowinsky, Eric K. "Mammalian target of rapamycin: a new molecular target for
breast cancer". Clinical breast cancer. 2003; 4: 126 (#144222)
104.Mita, Monica M; Mita, Alain; Rowinsky, Eric K. "The molecular target of rapamycin (mTOR) as a therapeutic
target against cancer". Cancer biology & therapy. 2003; 2: S169 (#144217)
105.O'Reilly, Seamus; O'Hearn, Elizabeth; Struck, Robert F; Rowinsky, Eric K; Molliver, Mark E. "The alkylating
agent penclomedine induces degeneration of purkinje cells in the rat cerebellum". Investigational new
drugs. 2003; 21: 269 (#144215)
106.Patnaik, Amita; Eckhardt, S Gail; Izbicka, Elzbieta; Tolcher, Anthony A; Hammond, Lisa A; Takimoto, Chris
H; Schwartz, Garry; McCreery, Heather; Goetz, Andrew; Mori, Masataka; Terada, Kazutoyo; Gentner, Lou;
Rybak, Mary-Ellen; Richards, Henry; Zhang, Steven; Rowinsky, Eric K. "A phase I, pharmacokinetic, and
biological study of the farnesyltransferase inhibitor tipifarnib in combination with gemcitabine in patients
with advanced malignancies". Clinical cancer research. 2003; 9: 4761 (#144212)
107.Rowinsky, Eric K. "Challenges of developing therapeutics that target signal transduction in patients with
gynecologic and other malignancies". Journal of clinical oncology. 2003; 21: 175s (#144223)
108.Rowinsky, Eric K. "Crossing the cancer cell membrane to improve clinical outcomes". Oncologist. 2003; 8
Suppl 3: 1 (#144234)
109.Rowinsky, Eric K. "Signal events: Cell signal transduction and its inhibition in cancer". Oncologist. 2003; 8
Suppl 3: 5 (#144233)
110.Rowinsky, Eric K; Rizzo, Jinee; Ochoa, Leonel; Takimoto, Chris H; Forouzesh, Bahram; Schwartz, Garry;
Hammond, Lisa A; Patnaik, Amita; Kwiatek, Joseph; Goetz, Andrew; Denis, Louis; McGuire, Jeffrey; Tolcher,
Anthony W. "A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3
weeks in patients with advanced solid malignancies". Journal of clinical oncology. 2003; 21: 148 (#144232)
111.Schwartz, G H; Patnaik, A; Hammond, L A; Rizzo, J; Berg, K; Von Hoff, D D; Rowinsky, E K. "A phase I
study of bizelesin, a highly potent and selective DNA-interactive agent, in patients with advanced solid
malignancies". Annals of oncology. 2003; 14: 775 (#144225)
112.Sledge, George W; Neuberg, Donna; Bernardo, Patricia; Ingle, James N; Martino, Silvana; Rowinsky, Eric
K; Wood, William C. "Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and
paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193)". Journal of
clinical oncology. 2003; 21: 588 (#144228)
113.Takimoto, Chris H; Rowinsky, Eric K. "Dose-intense paclitaxel: deja vu all over again?". Journal of clinical
oncology. 2003; 21: 2810 (#144216)
114.Tolcher, A W; Gerson, S L; Denis, L; Geyer, C; Hammond, L A; Patnaik, A; Goetz, A D; Schwartz, G;
Edwards, T; Reyderman, L; Statkevich, P; Cutler, D L; Rowinsky, E K. "Marked inactivation of O6alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules". British journal of
cancer. 2003; 88: 1004 (#144227)
115.Tolcher, Anthony W; Ochoa, Leonel; Hammond, Lisa A; Patnaik, Amita; Edwards, Tam; Takimoto, Chris;
Smith, Lon; de Bono, Johann; Schwartz, Garry; Mays, Theresa; Jonak, Zdenka L; Johnson, Randall;
DeWitte, Mark; Martino, Helen; Audette, Charlene; Maes, Kate; Chari, Ravi V J; Lambert, John M; Rowinsky,
Eric K. "Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase
I, pharmacokinetic, and biologic correlative study". Journal of clinical oncology. 2003; 21: 211 (#144230)
116.Baker, Sharyn D; Verweij, Jaap; Rowinsky, Eric K; Donehower, Ross C; Schellens, Jan H M; Grochow,
Louise B; Sparreboom, Alex. "Role of body surface area in dosing of investigational anticancer agents in
adults, 1991-2001". Journal of the National Cancer Institute. 2002; 94: 1883 (#144235)
117.de Bono, Johann S; Rowinsky, Eric K. "The ErbB receptor family: a therapeutic target for cancer". Trends in
molecular medicine. 2002; 8: S19 (#144248)
118.de Bono, Johann S; Rowinsky, Eric K. "Therapeutics targeting signal transduction for patients with colorectal
carcinoma". British medical bulletin. 2002; 64: 227 (#144243)
119.de Bono, Johann S; Stephenson, Joseph Jr; Baker, Sharyn D; Hidalgo, Manuel; Patnaik, Amita; Hammond,
Lisa A; Weiss, Geoffrey; Goetz, Andrew; Siu, Lillian; Simmons, Cecelia; Jolivet, Jacques; Rowinsky, Eric K.
"Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: a phase I and
pharmacokinetic study in patients with advanced solid malignancies". Journal of clinical oncology. 2002; 20:
96 (#144246)
120.Hao, Desiree; Rowinsky, Eric K. "Inhibiting signal transduction: recent advances in the development of
receptor tyrosine kinase and Ras inhibitors". Cancer investigation. 2002; 20: 387 (#144244)
121.Lobell, Robert B; Liu, Dongming; Buser, Carolyn A; Davide, Joseph P; DePuy, Elizabeth; Hamilton, Kelly;
Koblan, Kenneth S; Lee, Yih; Mosser, Scott; Motzel, Sherri L; Abbruzzese, James L; Fuchs, Charles S;
Rowinsky, Eric K; Rubin, Eric H; Sharma, Sunil; Deutsch, Paul J; Mazina, Kathryn E; Morrison, Briggs W;
Wildonger, Lynne; Yao, Siu-Long; Kohl, Nancy E. "Preclinical and clinical pharmacodynamic assessment of
L-778,123, a dual inhibitor of farnesyl:protein transferase and geranylgeranyl:protein transferase type-I".
Molecular cancer therapeutics. 2002; 1: 747 (#144240)
122.Mould, Diane R; Holford, Nicholas H G; Schellens, Jan H M; Beijnen, Jos H; Hutson, Paul R; Rosing, Hilde;
ten Bokkel Huinink, Willem W; Rowinsky, Eric K; Schiller, Joan H; Russo, Mark; Ross, Graham. "Population
pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors". Clinical
pharmacology & therapeutics. 2002; 71: 334 (#144241)
123.Patnaik, Amita; Rowinsky, Eric K; Villalona, Miguel A; Hammond, Lisa A; Britten, Carolyn D; Siu, Lillian L;
Goetz, Andrew; Felton, Sally A; Burton, Susan; Valone, Frank H; Eckhardt, S Gail. "A phase I study of
pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced
solid malignancies". Clinical cancer research. 2002; 8: 2142 (#144239)
124.Ranson, Malcolm; Hammond, Lisa A; Ferry, David; Kris, Mark; Tullo, Andrew; Murray, Philip I; Miller, Vince;
Averbuch, Steve; Ochs, Judy; Morris, Charles; Feyereislova, Andrea; Swaisland, Helen; Rowinsky, Eric K.
"ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and
active in patients with solid, malignant tumors: results of a phase I trial". Journal of clinical oncology. 2002;
20: 2240 (#144242)
125.Rowinsky, Eric K. "Taxane analogues: distinguishing royal robes from the "Emperor's New Clothes"".
Clinical cancer research. 2002; 8: 2759 (#144237)
126.Rowinsky, Eric K. "Weekly topotecan: an alternative to topotecan's standard daily x 5 schedule?".
Oncologist. 2002; 7: 324 (#144247)
127.Siu, Lillian L; Rowinsky, Eric K; Hammond, Lisa A; Weiss, Geoffrey R; Hidalgo, Manuel; Clark, Gary M;
Moczygemba, Judy; Choi, Les; Linnartz, Ron; Barbet, Nicholas C; Sklenar, Ivo T; Capdeville, Renaud; Gan,
Gregory; Porter, Carl W; Von Hoff, Daniel D; Eckhardt, S Gail. "A phase I and pharmacokinetic study of
SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week
schedule in patients with Advanced solid malignancies". Clinical cancer research. 2002; 8: 2157 (#144238)
128.Tolcher, Anthony W; Takimoto, Chris H; Rowinsky, Eric K. "The multifunctional, multi-institutional, and
sometimes even global phase I study: a better life for phase I evaluations or just "living large"?". Journal of
clinical oncology. 2002; 20: 4276 (#144236)
129.Villalona-Calero, Miguel A; Eckhardt, S Gail; Weiss, Geoffrey; Hidalgo, Manuel; Beijnen, Jos H; van
Kesteren, Charlotte; Rosing, Hilde; Campbell, Elizabeth; Kraynak, Maura; Lopez-Lazaro, Luis; Guzman,
Cecilia; Von Hoff, Daniel D; Jimeno, Jose; Rowinsky, Eric K. "A phase I and pharmacokinetic study of
ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies". Clinical cancer research.
2002; 8: 75 (#144245)
130.Britten, C D; Rowinsky, E K; Soignet, S; Patnaik, A; Yao, S L; Deutsch, P; Lee, Y; Lobell, R B; Mazina, K E;
McCreery, H; Pezzuli, S; Spriggs, D. "A phase I and pharmacological study of the farnesyl protein
transferase inhibitor L-778,123 in patients with solid malignancies". Clinical cancer research. 2001; 7: 3894
(#144249)
131.Gore, S D; Weng, L J; Zhai, S; Figg, W D; Donehower, R C; Dover, G J; Grever, M; Griffin, C A; Grochow, L
B; Rowinsky, E K; Zabalena, Y; Hawkins, A L; Burks, K; Miller, C B. "Impact of the putative differentiating
agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia". Clinical cancer
research. 2001; 7: 2330 (#144251)
132.Hidalgo, M; Aylesworth, C; Hammond, L A; Britten, C D; Weiss, G; Stephenson, J Jr; Schwartz, G; Patnaik,
A; Smith, L; Molpus, K; Felton, S; Gupta, E; Ferrante, K J; Tortora, A; Sonnichsen, D S; Skillings, J;
Rowinsky, E K. "Phase I and pharmacokinetic study of BMS-184476, a taxane with greater potency and
solubility than paclitaxel". Journal of clinical oncology. 2001; 19: 2493 (#144257)
133.Hidalgo, M; Siu, L L; Nemunaitis, J; Rizzo, J; Hammond, L A; Takimoto, C; Eckhardt, S G; Tolcher, A;
Britten, C D; Denis, L; Ferrante, K; Von Hoff, D D; Silberman, S; Rowinsky, E K. "Phase I and
pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients
with advanced solid malignancies". Journal of clinical oncology. 2001; 19: 3267 (#144254)
134.Holmes, F A; Rowinsky, E K. "Pharmacokinetic profiles of doxorubicin in combination with taxanes".
Seminars in oncology. 2001; 28: 8 (#144252)
135.Lakhanpal, S; Donehower, R C; Rowinsky, E K. "Phase II study of 4-ipomeanol, a naturally occurring
alkylating furan, in patients with advanced hepatocellular carcinoma". Investigational new drugs. 2001; 19:
69 (#144259)
136.O'Reilly, S; Hartman, N R; Bowling, K M; Rowinsky, E K; Donehower, R C; Collins, J; Strong, J M.
"Bioavailability of penclomedine and systemic exposure to 4-O-demethylpenclomedine in patients receiving
oral and intravenous penclomedine". Cancer chemotherapy & pharmacology. 2001; 48: 223 (#144250)
137.Schwartz, G; Johnson, T R; Goetz, A; Burris, H; Smetzer, L; Lampkin, T; Sailstad, J; Hohneker, J A; Von
Hoff, D D; Rowinsky, E K. "A phase I and pharmacokinetic study of 1843U89, a noncompetitive inhibitor of
thymidylate synthase, in patients with advanced solid malignancies". Clinical cancer research. 2001; 7:
1901 (#144253)
138.Tolcher, A W; Eckhardt, S G; Kuhn, J; Hammond, L; Weiss, G; Rizzo, J; Aylesworth, C; Hidalgo, M; Patnaik,
A; Schwartz, G; Felton, S; Campbell, E; Rowinsky, E K. "Phase I and pharmacokinetic study of NSC
655649, a rebeccamycin analog with topoisomerase inhibitory properties". Journal of clinical oncology.
2001; 19: 2937 (#144255)
139.Villalona-Calero, M A; Blum, J L; Jones, S E; Diab, S; Elledge, R; Khoury, P; Von Hoff, D; Kraynak, M;
Moczygemba, J; Kromelis, P; Griffin, T; Rowinsky, E K. "A phase I and pharmacologic study of capecitabine
and paclitaxel in breast cancer patients". Annals of oncology. 2001; 12: 605 (#144256)
140.Villalona-Calero, M A; Eder, J P; Toppmeyer, D L; Allen, L F; Fram, R; Velagapudi, R; Myers, M; Amato, A;
Kagen-Hallet, K; Razvillas, B; Kufe, D W; Von Hoff , D D; Rowinsky, E K. "Phase I and pharmacokinetic
study of LU79553, a DNA intercalating bisnaphthalimide, in patients with solid malignancies". Journal of
clinical oncology. 2001; 19: 857 (#144258)
141.Baker, S D; Diasio, R B; O'Reilly, S; Lucas, V S; Khor, S P; Sartorius, S E; Donehower, R C; Grochow, L B;
Spector, T; Hohneker, J A; Rowinsky, E K. "Phase I and pharmacologic study of oral fluorouracil on a
chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil".
Journal of clinical oncology. 2000; 18: 915 (#144271)
142.Bonomi, P; Perez-Soler, R; Chachoua, A; Huberman, M; Karp, D; Rigas, J; Hammond, L; Rowinsky, E;
Preston, G; Ferrente, KJ; Allen, LF. "A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitor (TKI), CP-358,774, following platinum-based chemotherapy in patients (pts) with advanced
non-small cell lung cancer (NSCLC)". Clinical cancer research. 2000; 6: 4544S (#54443)
143.Britten, C D; Baker, S D; Denis, L J; Johnson, T; Drengler, R; Siu, L L; Duchin, K; Kuhn, J; Rowinsky, E K.
"Oral paclitaxel and concurrent cyclosporin A: targeting clinically relevant systemic exposure to paclitaxel".
Clinical cancer research. 2000; 6: 3459 (#144265)
144.Britten, C D; Rowinsky, E K; Baker, S D; Weiss, G R; Smith, L; Stephenson, J; Rothenberg, M; Smetzer, L;
Cramer, J; Collins, W; Von Hoff, D D; Eckhardt, S G. "A phase I and pharmacokinetic study of the
mitochondrial-specific rhodacyanine dye analog MKT 077". Clinical cancer research. 2000; 6: 42 (#144272)
145.Eckhardt, S G; Baker, S D; Britten, C D; Hidalgo, M; Siu, L; Hammond, L A; Villalona-Calero, M A; Felton,
S; Drengler, R; Kuhn, J G; Clark, G M; Smith, S L; MacDonald, J R; Smith, C; Moczygemba, J; Weitman, S;
Von Hoff, D D; Rowinsky, E K. "Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived
cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid
malignancies". Journal of clinical oncology. 2000; 18: 4086 (#144261)
146.Gallo, J M; Laub, P B; Rowinsky, E K; Grochow, L B; Baker, S D. "Population pharmacokinetic model for
topotecan derived from phase I clinical trials". Journal of clinical oncology. 2000; 18: 2459 (#144267)
147.Hammond, L A; Hilsenbeck, S G; Eckhardt, S G; Marty, J; Mangold, G; MacDonald, J R; Rowinsky, E K; Von
Hoff, D D; Weitman, S. "Enhanced antitumour activity of 6-hydroxymethylacylfulvene in combination with
topotecan or paclitaxel in the MV522 lung carcinoma xenograft model". European journal of cancer (1990).
2000; 36: 2430 (#144262)
148.Hidalgo, M; Rowinsky, E K. "The rapamycin-sensitive signal transduction pathway as a target for cancer
therapy". Oncogene. 2000; 19: 6680 (#144260)
149.Hidalgo, M; Villalona-Calero, M A; Eckhardt, S G; Drengler, R L; Rodriguez, G; Hammond, L A; Diab, S G;
Weiss, G; Garner, A M; Campbell, E; Davidson, K; Louie, A; O'Neil, J D; von Borstel, R; Von Hoff, D D;
Rowinsky, E K. "Phase I and pharmacologic study of PN401 and fluorouracil in patients with advanced solid
malignancies". Journal of clinical oncology. 2000; 18: 167 (#144275)
150.John, W; Picus, J; Blanke, C D; Clark, J W; Schulman, L N; Rowinsky, E K; Thornton, D E; Loehrer, P J.
"Activity of multitargeted antifolate (pemetrexed disodium, LY231514) in patients with advanced colorectal
carcinoma: results from a phase II study". Cancer. 2000; 88: 1807 (#144268)
151.Ochoa, L; Hurwitz, H I; Wilding, G; Cohen, D; Thomas, J P; Schwartz, G; Monroe, P; Petros, W P; Ertel, V
P; Hsieh, A; Hoffman, C; Drengler, R; Magnum, S; Rowinsky, E K. "Pharmacokinetics and bioequivalence of
a combined oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5fluorouracil in patients with advanced solid malignancies". Annals of oncology. 2000; 11: 1313 (#144264)
152.Patnaik, A; Rowinsky, E K; Tammara, B K; Hidalgo, M; Drengler, R L; Garner, A M; Siu, L L; Hammond, L
A; Felton, S A; Mallikaarjun, S; Von Hoff, D D; Eckhardt, S G. "Phase I and pharmacokinetic study of the
differentiating agent vesnarinone in combination with gemcitabine in patients with advanced cancer".
Journal of clinical oncology. 2000; 18: 3974 (#144263)
153.Rowinsky, E K. "The pursuit of optimal outcomes in cancer therapy in a new age of rationally designed
target-based anticancer agents". Drugs. 2000; 60 Suppl 1: 1 (#144273)
154.Rowinsky, E K; Humphrey, R; Hammond, L A; Aylesworth, C; Smetzer, L; Hidalgo, M; Morrow, M; Smith, L;
Garner, A; Sorensen, J M; Von Hoff, D D; Eckhardt, S G. "Phase I and pharmacologic study of the specific
matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with
solid malignancies". Journal of clinical oncology. 2000; 18: 178 (#144274)
155.Rowinsky, E K; Johnson, T R; Geyer, C E Jr; Hammond, L A; Eckhardt, S G; Drengler, R; Smetzer, L;
Coyle, J; Rizzo, J; Schwartz, G; Tolcher, A; Von Hoff, D D; De Jager, R L. "DX-8951f, a hexacyclic
camptothecin analog, on a daily-times-five schedule: a phase I and pharmacokinetic study in patients with
advanced solid malignancies". Journal of clinical oncology. 2000; 18: 3151 (#144266)
156.Tolcher, A W; Aylesworth, C; Rizzo, J; Izbicka, E; Campbell, E; Kuhn, J; Weiss, G; Von Hoff, D D;
Rowinsky, E K. "A phase I study of rhizoxin (NSC 332598) by 72-hour continuous intravenous infusion in
patients with advanced solid tumors". Annals of oncology. 2000; 11: 333 (#144270)
157.Zucker, S; Eckhardt, S G; Rowinsky, E K. "Plasma MMPs as surrogates of BAY 12-9566". Journal of clinical
oncology. 2000; 18: 1805 (#144269)
158.Baker, S D; Wirth, M; Statkevich, P; Reidenberg, P; Alton, K; Sartorius, S E; Dugan, M; Cutler, D; Batra, V;
Grochow, L B; Donehower, R C; Rowinsky, E K. "Absorption, metabolism, and excretion of 14Ctemozolomide following oral administration to patients with advanced cancer". Clinical cancer research.
1999; 5: 309 (#144291)
159.Britten, C D; Hilsenbeck, S G; Eckhardt, S G; Marty, J; Mangold, G; MacDonald, J R; Rowinsky, E K; Von
Hoff, D D; Weitman, S. "Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with
irinotecan and 5-fluorouracil in the HT29 human colon tumor xenograft model". Cancer research. 1999; 59:
1049 (#144288)
160.Britten, C D; Izbicka, E; Hilsenbeck, S; Lawrence, R; Davidson, K; Cerna, C; Gomez, L; Rowinsky, E K;
Weitman, S; Von Hoff, D D. "Activity of the multitargeted antifolate LY231514 in the human tumor cloning
assay". Cancer chemotherapy & pharmacology. 1999; 44: 105 (#144293)
161.Britten, C D; Rowinsky, E K; Baker, S D; Agarwala, S S; Eckardt, J R; Barrington, R; Diab, S G; Hammond,
L A; Johnson, T; Villalona-Calero, M; Fraass, U; Statkevich, P; Von Hoff, D D; Eckhardt, S G. "A Phase I
and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies".
Clinical cancer research. 1999; 5: 1629 (#144283)
162.Diab, S G; Baker, S D; Joshi, A; Burris, H A; Cobb, P W; Villalona-Calero, M A; Eckhardt, S G; Weiss, G R;
Rodriguez, G I; Drengler, R; Kraynak, M; Hammond, L; Finizio, M; Von Hoff, D D; Rowinsky, E K. "A phase
I and pharmacokinetic study of losoxantrone and paclitaxel in patients with advanced solid tumors". Clinical
cancer research. 1999; 5: 299 (#144292)
163.Eckhardt, S G; Rizzo, J; Sweeney, K R; Cropp, G; Baker, S D; Kraynak, M A; Kuhn, J G; Villalona-Calero, M
A; Hammond, L; Weiss, G; Thurman, A; Smith, L; Drengler, R; Eckardt, J R; Moczygemba, J; Hannah, A L;
Von Hoff, D D; Rowinsky, E K. "Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in
patients with advanced solid tumors". Journal of clinical oncology. 1999; 17: 1095 (#144286)
164.Fracasso, P M; Tan, B R Jr; Grieff, M; Stephenson, J Jr; Liapis, H; Umbeck, N L; Von Hoff, D D; Rowinsky,
E K. "Membranoproliferative glomerulonephritis following gemcitabine and vinorelbine chemotherapy for
peritoneal mesothelioma". Journal of the National Cancer Institute. 1999; 91: 1779 (#144278)
165.Hammond, L A; Eckardt, J R; Baker, S D; Eckhardt, S G; Dugan, M; Forral, K; Reidenberg, P; Statkevich, P;
Weiss, G R; Rinaldi, D A; Von Hoff, D D; Rowinsky, E K. "Phase I and pharmacokinetic study of
temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies". Journal of
clinical oncology. 1999; 17: 2604 (#144282)
166.Hidalgo, M; Izbicka, E; Cerna, C; Gomez, L; Rowinsky, E K; Weitman, S D; Von Hoff, D D. "Comparative
activity of the cyclopropylpyrroloindole compounds adozelesin, bizelesin and carzelesin in a human tumor
colony-forming assay". Anti-cancer drugs. 1999; 10: 295 (#144287)
167.Hidalgo, M; Izbicka, E; Eckhardt, S G; MacDonald, J R; Cerna, C; Gomez, L; Rowinsky, E K; Weitman, S D;
Von Hoff, D D. "Antitumor activity of MGI 114 (6-hydroxymethylacylfulvene, HMAF), a semisynthetic
derivative of illudin S, against adult and pediatric human tumor colony-forming units". Anti-cancer drugs.
1999; 10: 837 (#144279)
168.Lawrence, R A; Izbicka, E; De Jager, R L; Tohgo, A; Clark, G M; Weitman, S D; Rowinsky, E K; Von Hoff, D
D. "Comparison of DX-8951f and topotecan effects on tumor colony formation from freshly explanted adult
and pediatric human tumor cells". Anti-cancer drugs. 1999; 10: 655 (#144281)
169.Petit, T; Aylesworth, C; Burris, H; Ravdin, P; Rodriguez, G; Smith, L; Peacock, N; Smetzer, L; Bellet, R;
Von Hoff, D D; Rowinsky, E K. "A phase I study of docetaxel and 5-fluorouracil in patients with advanced
solid malignancies". Annals of oncology. 1999; 10: 223 (#144290)
170.Rowinsky, E K. "Novel radiation sensitizers targeting tissue hypoxia". Oncology. 1999; 13: 61 (#144280)
171.Rowinsky, E K. "On pushing the outer edge of the outer edge of paclitaxel's dosing envelope". Clinical
cancer research. 1999; 5: 481 (#144289)
172.Rowinsky, E K; Jiroutek, M; Bonomi, P; Johnson, D; Baker, S D. "Paclitaxel steady-state plasma
concentration as a determinant of disease outcome and toxicity in lung cancer patients treated with
paclitaxel and cisplatin". Clinical cancer research. 1999; 5: 767 (#144285)
173.Rowinsky, E K; Windle, J J; Von Hoff, D D. "Ras protein farnesyltransferase: A strategic target for
anticancer therapeutic development". Journal of clinical oncology. 1999; 17: 3631 (#144277)
174.Villalona-Calero, M A; Petit, T; Kuhn, J; Cobb, P; Kraynak, M; Eckhardt, S G; Drengler, R; Simmons, C;
Santabarbara, P; Von Hoff, D D; Rowinsky, E K. "A phase I and pharmacological study of protracted
infusions of crisnatol mesylate in patients with solid malignancies". Clinical cancer research. 1999; 5: 3369
(#144276)
175.Villalona-Calero, M A; Weiss, G R; Burris, H A; Kraynak, M; Rodrigues, G; Drengler, R L; Eckhardt, S G;
Reigner, B; Moczygemba, J; Burger, H U; Griffin, T; Von Hoff, D D; Rowinsky, E K. "Phase I and
pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients
with advanced solid malignancies". Journal of clinical oncology. 1999; 17: 1915 (#144284)
176.Adjei, A A; Charron, M; Rowinsky, E K; Svingen, P A; Miller, J; Reid, J M; Sebolt-Leopold, J; Ames, M M;
Kaufmann, S H. "Effect of pyrazoloacridine (NSC 366140) on DNA topoisomerases I and II". Clinical cancer
research. 1998; 4: 683 (#144303)
177.Eckhardt, S G; Baker, S D; Eckardt, J R; Burke, T G; Warner, D L; Kuhn, J G; Rodriguez, G; Fields, S;
Thurman, A; Smith, L; Rothenberg, M L; White, L; Wissel, P; Kunka, R; DePee, S; Littlefield, D; Burris, H
A; Von Hoff, D D; Rowinsky, E K. "Phase I and pharmacokinetic study of GI147211, a water-soluble
camptothecin analogue, administered for five consecutive days every three weeks". Clinical cancer
research. 1998; 4: 595 (#144304)
178.Gore, S D; Rowinsky, E K; Miller, C B; Griffin, C; Chen, T L; Borowitz, M; Donehower, R C; Burks, K L;
Armstrong, D K; Burke, P J; Grever, M R; Kaufmann, S H. "A phase II "window" study of topotecan in
untreated patients with high risk adult acute lymphoblastic leukemia". Clinical cancer research. 1998; 4:
2677 (#144295)
179.Hammond, L A; Eckardt, J R; Ganapathi, R; Burris, H A; Rodriguez, G A; Eckhardt, S G; Rothenberg, M L;
Weiss, G R; Kuhn, J G; Hodges, S; Von Hoff, D D; Rowinsky, E K. "A phase I and translational study of
sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide". Clinical cancer
research. 1998; 4: 1459 (#144299)
180.Hidalgo, M; Rodriguez, G; Kuhn, J G; Brown, T; Weiss, G; MacGovren, J P; Von Hoff, D D; Rowinsky, E K.
"A Phase I and pharmacological study of the glutamine antagonist acivicin with the amino acid solution
aminosyn in patients with advanced solid malignancies". Clinical cancer research. 1998; 4: 2763 (#144294)
181.Kennedy, M J; Zahurak, M L; Donehower, R C; Noe, D; Grochow, L B; Sartorius, S; Chen, T L; Bowling, K;
Duerr, M; Rowinsky, E K. "Sequence-dependent hematological toxicity associated with the 3-hour
paclitaxel/cyclophosphamide doublet". Clinical cancer research. 1998; 4: 349 (#144306)
182.O'Reilly, S; Baker, S D; Sartorius, S; Rowinsky, E K; Finizio, M; Lubiniecki, G M; Grochow, L B; Gray, J E;
Pieniaszek, H J Jr; Donehower, R C. "A phase I and pharmacologic study of DMP 840 administered by 24hour infusion". Annals of oncology. 1998; 9: 101 (#144307)
183.Rodriguez, G I; Kuhn, J G; Weiss, G R; Hilsenbeck, S G; Eckardt, J R; Thurman, A; Rinaldi, D A; Hodges, S;
Von Hoff, D D; Rowinsky, E K. "A bioavailability and pharmacokinetic study of oral and intravenous
hydroxyurea". Blood. 1998; 91: 1533 (#144302)
184.Rothenberg, M L; Kuhn, J G; Schaaf, L J; Drengler, R L; Eckhardt, S G; Villalona-Calero, M A; Hammond,
L; Miller, L L; Petit, R G; Rowinsky, E K; Von Hoff, D D. "Alternative dosing schedules for irinotecan".
Oncology. 1998; 12: 68 (#144298)
185.Rowinsky EK. "Novel Natural Products and Other Anticancer Therapeutics: 1998". Cancer control. 1998; 5:
12 (#144301)
186.Rowinsky, E K; Baker, S D; Burks, K; O'Reilly, S; Donehower, R C; Grochow, L B. "High-dose topotecan
with granulocyte-colony stimulating factor in fluoropyrimidine-refractory colorectal cancer: a phase II and
pharmacodynamic study". Annals of oncology. 1998; 9: 173 (#144305)
187.Rowinsky, E K; Smith, L; Wang, Y M; Chaturvedi, P; Villalona, M; Campbell, E; Aylesworth, C; Eckhardt, S
G; Hammond, L; Kraynak, M; Drengler, R; Stephenson, J Jr; Harding, M W; Von Hoff, D D. "Phase I and
pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug
resistance conferred by overexpression of both MDR1 and MRP". Journal of clinical oncology. 1998; 16:
2964 (#144296)
188.Siu, L L; Attardo, G; Izbicka, E; Lawrence, R; Cerna, C; Gomez, L; Davidson, K; Finkle, C; Marsolais, C;
Rowinsky, E K; Von Hoff, D D. "Activity of (-)-2'-deoxy-3'-oxacytidine (BCH-4556) against human tumor
colony-forming units". Annals of oncology. 1998; 9: 885 (#144297)
189.Siu, L L; Rowinsky, E K. "A risk-benefit assessment of irinotecan in solid tumours". Drug safety. 1998; 18:
395 (#144300)
190.Siu, L L; Von Hoff, D D; Rephaeli, A; Izbicka, E; Cerna, C; Gomez, L; Rowinsky, E K; Eckhardt, S G.
"Activity of pivaloyloxymethyl butyrate, a novel anticancer agent, on primary human tumor colony-forming
units". Investigational new drugs. 1998; 16: 113 (#144308)
191.Adjei, A A; Budihardjo, I I; Rowinsky, E K; Kottke, T J; Svingen, P A; Buckwalter, C A; Grochow, L B;
Donehower, R C; Kaufmann, S H. "Cytotoxic synergy between pyrazoloacridine (NSC 366140) and cisplatin
in vitro: inhibition of platinum-DNA adduct removal". Clinical cancer research. 1997; 3: 761 (#144317)
192.Hortobagyi GN; Sledge GW Jr; Rowinsky EK. "What New Drugs, Biologics, and Treatment Approaches Show
Promise in Breast Cancer?". Cancer control. 1997; 4: 34 (#144315)
193.Kaufmann, S H; Svingen, P A; Gore, S D; Armstrong, D K; Cheng, Y C; Rowinsky, E K. "Altered formation
of topotecan-stabilized topoisomerase I-DNA adducts in human leukemia cells". Blood. 1997; 89: 2098
(#144320)
194.O'Reilly, S; Fleming, G F; Barker, S D; Walczak, J R; Bookman, M A; McGuire, W P 3rd; Schilder, R J;
Alvarez, R D; Armstrong, D K; Horowitz, I R; Ozols, R F; Rowinsky, E K. "Phase I trial and pharmacologic
trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a
Gynecologic Oncology Group study". Journal of clinical oncology. 1997; 15: 177 (#144326)
195.O'Reilly, S; Grochow, L B; Donehower, R C; Chen, T L; Bowling, K; Hartman, N R; Struck, R F; Rowinsky, E
K. "Phase I and pharmacologic study of penclomedine, a novel alkylating agent, in patients with solid
tumors". Journal of clinical oncology. 1997; 15: 1974 (#144318)
196.O'Reilly, S; Rowinsky, E K. "Experimental chemotherapeutic agents for the treatment of colorectal
carcinoma". Hematology-oncology clinics of North America. 1997; 11: 721 (#144313)
197.Raymond, E; Burris, H A; Rowinsky, E K; Eckardt, J R; Rodriguez, G; Smith, L; Weiss, G; Von Hoff, D D.
"Phase I study of daily times five topotecan and single injection of cisplatin in patients with previously
untreated non-small-cell lung carcinoma". Annals of oncology. 1997; 8: 1003 (#144312)
198.Raymond, E; Hanauske, A; Faivre, S; Izbicka, E; Clark, G; Rowinsky, E K; Von Hoff, D D. "Effects of
prolonged versus short-term exposure paclitaxel (Taxol) on human tumor colony-forming units". Anticancer drugs. 1997; 8: 379 (#144319)
199.Rowinsky, E K. "Paclitaxel pharmacology and other tumor types". Seminars in oncology. 1997; 24: S19
(#144309)
200.Rowinsky, E K. "The development and clinical utility of the taxane class of antimicrotubule chemotherapy
agents". Annual review of medicine. 1997; 48: 353 (#144324)
201.Rowinsky, E K. "The taxanes: dosing and scheduling considerations". Oncology. 1997; 11: 7 (#144323)
202.Rowinsky, E K; Flood, W A; Sartorius, S E; Bowling, K M; Ettinger, D S. "Phase I study of paclitaxel on a 3hour schedule followed by carboplatin in untreated patients with stage IV non-small cell lung cancer".
Investigational new drugs. 1997; 15: 129 (#144325)
203.Rowinsky, E K; Kaufmann, S H. "Topotecan in combination chemotherapy". Seminars in oncology. 1997;
24: S20 (#144310)
204.Rowinsky, E K; Long, G S; Noe, D A; Grochow, L B; Bowling, M K; Sartorius, S E; Donehower, R C. "Phase
I and pharmacological study of CI-980, a novel synthetic antimicrotubule agent". Clinical cancer research.
1997; 3: 401 (#144322)
205.Rowinsky, E K; Verweij, J. "Review of phase I clinical studies with topotecan". Seminars in oncology. 1997;
24: S20 (#144311)
206.Sledge GW Jr; Rowinsky EK; Hortobagyi GN; Vaughan W; Horton J. "What are the Roles of the Taxanes in
Breast Cancer". Cancer control. 1997; 4: 23 (#144316)
207.Su, H; Chen, T L; Hausheer, F H; Rowinsky, E K. "Novel high-performance liquid chromatographic assay
using fluorescence detection for the quantitation of plasma gamma-methylene-10-deazaaminopterin and its
major metabolite, 7-hydroxy-gamma-methylene-10-deazaaminopterin, in patients with solid cancers in a
phase I trial". Journal of chromatography. B. Biomedical sciences & applications. 1997; 695: 401
(#144314)
208.Baker, S D; Khor, S P; Adjei, A A; Doucette, M; Spector, T; Donehower, R C; Grochow, L B; Sartorius, S E;
Noe, D A; Hohneker, J A; Rowinsky, E K. "Pharmacokinetic, oral bioavailability, and safety study of
fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase". Journal of
clinical oncology. 1996; 14: 3085 (#144329)
209.Hartman, N R; O'Reilly, S; Rowinsky, E K; Collins, J M; Strong, J M. "Murine and human in vivo
penclomedine metabolism". Clinical cancer research. 1996; 2: 953 (#144335)
210.Kaufmann, S H; Gore, S D; Letendre, L; Svingen, P A; Kottke, T; Buckwalter, C A; Jones, R J; Grochow, L
B; Burke, P J; Donehower, R C; Rowinsky, E K. "Factors affecting topotecan sensitivity in human leukemia
samples". Annals of the New York Academy of Sciences. 1996; 803: 128 (#144327)
211.Kaufmann, S H; Peereboom, D; Buckwalter, C A; Svingen, P A; Grochow, L B; Donehower, R C; Rowinsky,
E K. "Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines".
Journal of the National Cancer Institute. 1996; 88: 734 (#144333)
212.Kennedy, M J; Zahurak, M L; Donehower, R C; Noe, D A; Sartorius, S; Chen, T L; Bowling, K; Rowinsky, E
K. "Phase I and pharmacologic study of sequences of paclitaxel and cyclophosphamide supported by
granulocyte colony-stimulating factor in women with previously treated metastatic breast cancer". Journal
of clinical oncology. 1996; 14: 783 (#144338)
213.O'Reilly, S; Donehower, R C; Rowinsky, E K; Ord, S; Grochow, L B. "A phase II trial of topotecan in patients
with previously untreated pancreatic cancer". Anti-cancer drugs. 1996; 7: 410 (#144334)
214.O'Reilly, S; Hartman, N R; Grossman, S A; Strong, J M; Struck, R F; Eller, S; Lesser, G J; Donehower, R C;
Rowinsky, E K. "Tissue and tumor distribution of C-penclomedine in rats". Clinical cancer research. 1996;
2: 541 (#144337)
215.O'Reilly, S; Rowinsky, E K. "The clinical status of irinotecan (CPT-11), a novel water soluble camptothecin
analogue: 1996". Critical reviews in oncology-hematology. 1996; 24: 47 (#144332)
216.O'Reilly, S; Rowinsky, E K; Slichenmyer, W; Donehower, R C; Forastiere, A A; Ettinger, D S; Chen, T L;
Sartorius, S; Grochow, L B. "Phase I and pharmacologic study of topotecan in patients with impaired renal
function". Journal of clinical oncology. 1996; 14: 3062 (#144331)
217.Rowinsky, E K; Grochow, L B; Sartorius, S E; Bowling, M K; Kaufmann, S H; Peereboom, D; Donehower, R
C. "Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with
granulocyte colony-stimulating factor in patients with solid tumors". Journal of clinical oncology. 1996; 14:
1224 (#144336)
218.Rowinsky, E K; Kaufmann, S H; Baker, S D; Grochow, L B; Chen, T L; Peereboom, D; Bowling, M K;
Sartorius, S E; Ettinger, D S; Forastiere, A A; Donehower, R C. "Sequences of topotecan and cisplatin:
phase I, pharmacologic, and in vitro studies to examine sequence dependence". Journal of clinical oncology.
1996; 14: 3074 (#144330)
219.Rowinsky, E K; Kaufmann, S H; Baker, S D; Miller, C B; Sartorius, S E; Bowling, M K; Chen, T L;
Donehower, R C; Gore, S D. "A phase I and pharmacological study of topotecan infused over 30 minutes for
five days in patients with refractory acute leukemia". Clinical cancer research. 1996; 2: 1921 (#144328)
220.Rowinsky, E K; Lucas, V S; Hsieh, A L; Wargin, W A; Hohneker, J A; Lubejko, B; Sartorius, S E;
Donehower, R C. "The effects of food and divided dosing on the bioavailability of oral vinorelbine". Cancer
chemotherapy & pharmacology. 1996; 39: 9 (#144339)
221.Kennedy, M J; Donehower, R C; Rowinsky, E K. "Treatment of metastatic breast cancer with combination
paclitaxel/cyclophosphamide". Seminars in oncology. 1995; 22: 23 (#144343)
222.Lesser, G J; Grossman, S A; Eller, S; Rowinsky, E K. "The distribution of systemically administered [3H]paclitaxel in rats: a quantitative autoradiographic study". Cancer chemotherapy & pharmacology. 1995; 37:
173 (#144348)
223.O'Reilly, S; Kennedy, M J; Rowinsky, E K; Donehower, R C. "Vinorelbine and the topoisomerase 1 inhibitors:
current and potential roles in breast cancer chemotherapy". Breast cancer research & treatment. 1995; 33:
1 (#144346)
224.Rowinsky, E K. "The suitability of selected new anticancer agents for infusional therapy and the effects of
others on infusional therapy practices". Journal of infusional chemotherapy. 1995; 5: 173 (#144340)
225.Rowinsky, E K; Donehower, R C. "Paclitaxel (taxol)". New England journal of medicine. 1995; 332: 1004
(#144344)
226.Rowinsky, E K; Flood, W A; Sartorius, S E; Bowling, M K; Wagner, J; Ettinger, D S. "Phase I study of
paclitaxel as a 3-hour infusion followed by carboplatin in untreated patients with stage IV non-small cell
lung cancer". Seminars in oncology. 1995; 22: 48 (#144342)
227.Rowinsky, E K; Noe, D A; Grochow, L B; Sartorious, S E; Bowling, M K; Chen, T L; Lubejko, B G;
Kaufmann, S H; Donehower, R C. "Phase I and pharmacologic studies of pyrazoloacridine, a novel DNA
intercalating agent, on single-dosing and multiple-dosing schedules". Journal of clinical oncology. 1995; 13:
1975 (#144341)
228.Slichenmyer, W J; Donehower, R C; Chen, T L; Bowling, M K; McGuire, W P; Rowinsky, E K. "Pretreatment
H2 receptor antagonists that differ in P450 modulation activity: comparative effects on paclitaxel clearance
rates and neutropenia". Cancer chemotherapy & pharmacology. 1995; 36: 227 (#144347)
229.Sollott, S J; Cheng, L; Pauly, R R; Jenkins, G M; Monticone, R E; Kuzuya, M; Froehlich, J P; Crow, M T;
Lakatta, E G; Rowinsky, E K. "Taxol inhibits neointimal smooth muscle cell accumulation after angioplasty in
the rat". Journal of clinical investigation. 1995; 95: 1869 (#144345)
230.Borkowski, J M; Duerr, M; Donehower, R C; Rowinsky, E K; Chen, T L; Ettinger, D S; Grochow, L B.
"Relation between age and clearance rate of nine investigational anticancer drugs from phase I
pharmacokinetic data". Cancer chemotherapy & pharmacology. 1994; 33: 493 (#144356)
231.Chaudhry, V; Rowinsky, E K; Sartorius, S E; Donehower, R C; Cornblath, D R. "Peripheral neuropathy from
taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies". Annals of
neurology. 1994; 35: 304 (#144353)
232.Finley, R S; Rowinsky, E K. "Patient care issues: the management of paclitaxel-related toxicities". Annals of
pharmacotherapy. 1994; 28: S27 (#144351)
233.Rowinsky, E K. "Update on the antitumor activity of paclitaxel in clinical trials". Annals of pharmacotherapy.
1994; 28: S18 (#144352)
234.Rowinsky, E K; Adjei, A; Donehower, R C; Gore, S D; Jones, R J; Burke, P J; Cheng, Y C; Grochow, L B;
Kaufmann, S H. "Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in
patients with refractory acute leukemia". Journal of clinical oncology. 1994; 12: 2193 (#144349)
235.Rowinsky, E K; Grochow, L B; Ettinger, D S; Sartorius, S E; Lubejko, B G; Chen, T L; Rock, M K;
Donehower, R C. "Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion
every 3 weeks". Cancer research. 1994; 54: 427 (#144354)
236.Rowinsky, E K; Noe, D A; Trump, D L; Winer, E P; Lucas, V S; Wargin, W A; Hohneker, J A; Lubejko, B;
Sartorius, S E; Ettinger, D S. "Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in
patients with solid tumors". Journal of clinical oncology. 1994; 12: 1754 (#144350)
237.Rowinsky, E K; Wright, M; Monsarrat, B; Donehower, R C. "Clinical pharmacology and metabolism of Taxol
(paclitaxel): update 1993". Annals of oncology. 1994; 5 Suppl 6: S7 (#144355)
238.Slichenmyer, W J; Rowinsky, E K; Grochow, L B; Kaufmann, S H; Donehower, R C. "Camptothecin
analogues: studies from the Johns Hopkins Oncology Center". Cancer chemotherapy & pharmacology. 1994;
34 Suppl: S53 (#144357)
239.Donehower, R C; Rowinsky, E K. "An overview of experience with TAXOL (paclitaxel) in the U.S.A". Cancer
treatment reviews. 1993; 19 Suppl C: 63 (#144365)
240.Monsarrat, B; Alvinerie, P; Wright, M; Dubois, J; Gueritte-Voegelein, F; Guenard, D; Donehower, R C;
Rowinsky, E K. "Hepatic metabolism and biliary excretion of Taxol in rats and humans". Journal of the
National Cancer Institute. Monographs. 1993; 39 (#144367)
241.Peereboom, D M; Donehower, R C; Eisenhauer, E A; McGuire, W P; Onetto, N; Hubbard, J L; Piccart, M;
Gianni, L; Rowinsky, E K. "Successful re-treatment with taxol after major hypersensitivity reactions".
Journal of clinical oncology. 1993; 11: 885 (#144361)
242.Rowinsky, E K. "Clinical pharmacology of Taxol". Journal of the National Cancer Institute. Monographs.
1993; 25 (#144368)
243.Rowinsky, E K; Chaudhry, V; Cornblath, D R; Donehower, R C. "Neurotoxicity of Taxol". Journal of the
National Cancer Institute. Monographs. 1993; 107 (#144369)
244.Rowinsky, E K; Chaudhry, V; Forastiere, A A; Sartorius, S E; Ettinger, D S; Grochow, L B; Lubejko, B G;
Cornblath, D R; Donehower, R C. "Phase I and pharmacologic study of paclitaxel and cisplatin with
granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting". Journal of clinical oncology.
1993; 11: 2010 (#144358)
245.Rowinsky, E K; Citardi, M J; Noe, D A; Donehower, R C. "Sequence-dependent cytotoxic effects due to
combinations of cisplatin and the antimicrotubule agents taxol and vincristine". Journal of cancer research &
clinical oncology. 1993; 119: 727 (#144366)
246.Rowinsky, E K; Donehower, R C. "The clinical pharmacology of paclitaxel (Taxol)". Seminars in oncology.
1993; 20: 16 (#144359)
247.Rowinsky, E K; Eisenhauer, E A; Chaudhry, V; Arbuck, S G; Donehower, R C. "Clinical toxicities
encountered with paclitaxel (Taxol)". Seminars in oncology. 1993; 20: 1 (#144360)
248.Rowinsky, E K; Noe, D A; Ettinger, D S; Christian, M C; Lubejko, B G; Fishman, E K; Sartorius, S E; Boyd,
M R; Donehower, R C. "Phase I and pharmacological study of the pulmonary cytotoxin 4-ipomeanol on a
single dose schedule in lung cancer patients: hepatotoxicity is dose limiting in humans". Cancer research.
1993; 53: 1794 (#144362)
249.Rowinsky, E K; Wright, M; Monsarrat, B; Lesser, G J; Donehower, R C. "Taxol: pharmacology, metabolism
and clinical implications". Cancer surveys. 1993; 17: 283 (#144364)
250.Slichenmyer, W J; Rowinsky, E K; Donehower, R C; Kaufmann, S H. "The current status of camptothecin
analogues as antitumor agents". Journal of the National Cancer Institute. 1993; 85: 271 (#144363)
251.Grochow, L B; Rowinsky, E K; Johnson, R; Ludeman, S; Kaufmann, S H; McCabe, F L; Smith, B R;
Hurowitz, L; DeLisa, A; Donehower, R C. "Pharmacokinetics and pharmacodynamics of topotecan in patients
with advanced cancer". Drug metabolism & disposition. 1992; 20: 706 (#144371)
252.Hendricks, C B; Rowinsky, E K; Grochow, L B; Donehower, R C; Kaufmann, S H. "Effect of P-glycoprotein
expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin
analogue". Cancer research. 1992; 52: 2268 (#144373)
253.Rowinsky, E K; Conley, B A; Jones, R J; Spivak, J L; Auerbach, M; Donehower, R C. "Hexamethylene
bisacetamide in myelodysplastic syndrome: effect of five-day exposure to maximal therapeutic
concentrations". Leukemia. 1992; 6: 526 (#144372)
254.Rowinsky, E K; Grochow, L B; Hendricks, C B; Ettinger, D S; Forastiere, A A; Hurowitz, L A; McGuire, W P;
Sartorius, S E; Lubejko, B G; Kaufmann, S H. "Phase I and pharmacologic study of topotecan: a novel
topoisomerase I inhibitor". Journal of clinical oncology. 1992; 10: 647 (#144374)
255.Rowinsky, E K; Onetto, N; Canetta, R M; Arbuck, S G. "Taxol: the first of the taxanes, an important new
class of antitumor agents". Seminars in oncology. 1992; 19: 646 (#144370)
256.Hendricks, C B; Grochow, L B; Rowinsky, E K; Forastiere, A A; McGuire, W P; Ettinger, D S; Sartorius, S;
Lubejko, B; Donehower, R C. "Phase I and pharmacokinetic study of hepsulfam (NSC 329680)". Cancer
research. 1991; 51: 5781 (#144377)
257.McGuire, W P; Rowinsky, E K. "Old drugs revisited, new drugs, and experimental approaches in ovarian
cancer therapy". Seminars in oncology. 1991; 18: 255 (#144381)
258.Rowinsky, E K. "Current developments in antitumor antibiotics, epipodophyllotoxins, and vinca alkaloids".
Current opinion in oncology. 1991; 3: 1060 (#144376)
259.Rowinsky, E K; Donehower, R C. "Taxol: twenty years later, the story unfolds". Journal of the National
Cancer Institute. 1991; 83: 1778 (#144375)
260.Rowinsky, E K; Donehower, R C. "The clinical pharmacology and use of antimicrotubule agents in cancer
chemotherapeutics". Pharmacology & therapeutics. 1991; 52: 35 (#144378)
261.Rowinsky, E K; Gilbert, M R; McGuire, W P; Noe, D A; Grochow, L B; Forastiere, A A; Ettinger, D S;
Lubejko, B G; Clark, B; Sartorius, S E. "Sequences of taxol and cisplatin: a phase I and pharmacologic
study". Journal of clinical oncology. 1991; 9: 1692 (#144380)
262.Rowinsky, E K; McGuire, W P; Guarnieri, T; Fisherman, J S; Christian, M C; Donehower, R C. "Cardiac
disturbances during the administration of taxol". Journal of clinical oncology. 1991; 9: 1704 (#144379)
263.Hantel, A; Donehower, R C; Rowinsky, E K; Vance, E; Clarke, B V; McGuire, W P; Ettinger, D S; Noe, D A;
Grochow, L B. "Phase I study and pharmacodynamics of piroxantrone (NSC 349174), a new
anthrapyrazole". Cancer research. 1990; 50: 3284 (#144385)
264.Jones, R J; Sharkis, S J; Miller, C B; Rowinsky, E K; Burke, P J; May, W S. "Bryostatin 1, a unique biologic
response modifier: anti-leukemic activity in vitro". Blood. 1990; 75: 1319 (#144386)
265.Noe, D A; Rowinsky, E K; Shen, H S; Clarke, B V; Grochow, L B; McGuire, W B; Hantel, A; Adams, D B;
Abeloff, M D; Ettinger, D S. "Phase I and pharmacokinetic study of brequinar sodium (NSC 368390)".
Cancer research. 1990; 50: 4595 (#144383)
266.Roberts, J R; Allison, D C; Donehower, R C; Rowinsky, E K. "Development of polyploidization in taxolresistant human leukemia cells in vitro". Cancer research. 1990; 50: 710 (#144387)
267.Rowinsky, E K; Cazenave, L A; Donehower, R C. "Taxol: a novel investigational antimicrotubule agent".
Journal of the National Cancer Institute. 1990; 82: 1247 (#144384)
268.Rowinsky, E K; Donehower, R C; Spivak, J L; Burke, P J; Griffin, C A; Jones, R J. "Effects of the
differentiating agent hexamethylene bisacetamide on normal and myelodysplastic hematopoietic
progenitors". Journal of the National Cancer Institute. 1990; 82: 1926 (#144382)
269.Grochow, L B; Noe, D A; Dole, G B; Rowinsky, E K; Ettinger, D S; Graham, M L; McGuire, W P; Donehower,
R C. "Phase I trial of trimetrexate glucuronate on a five-day bolus schedule: clinical pharmacology and
pharmacodynamics". Journal of the National Cancer Institute. 1989; 81: 124 (#144392)
270.McGuire, W P; Rowinsky, E K; Rosenshein, N B; Grumbine, F C; Ettinger, D S; Armstrong, D K; Donehower,
R C. "Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial
neoplasms". Annals of internal medicine. 1989; 111: 273 (#144390)
271.Roberts, J R; Rowinsky, E K; Donehower, R C; Robertson, J; Allison, D C. "Demonstration of the cell cycle
positions of taxol-induced "asters" and "bundles" by sequential measurements of tubulin
immunofluorescence, DNA content, and autoradiographic labeling of taxol-sensitive and -resistant cells".
Journal of histochemistry & cytochemistry. 1989; 37: 1659 (#144389)
272.Rowinsky, E K; Burke, P J; Karp, J E; Tucker, R W; Ettinger, D S; Donehower, R C. "Phase I and
pharmacodynamic study of taxol in refractory acute leukemias". Cancer research. 1989; 49: 4640
(#144391)
273.Rowinsky, E K; Grochow, L B; Hantel, A; Ettinger, D S; Vito, B L; Donehower, R C. "Assessment of Nmethylformamide (NMF) administered orally on a three times weekly schedule: a phase I study".
Investigational new drugs. 1989; 7: 317 (#144388)
274.Hantel, A; Rowinsky, E K; Donehower, R C. "Nifedipine and oncologic Raynaud phenomenon". Annals of
internal medicine. 1988; 108: 767 (#144396)
275.Hantel, A; Rowinsky, E K; Noe, D A; McGuire, W P; Grochow, L B; Vito, B L; Ettinger, D S; Donehower, R
C. "Clinical and pharmacologic reappraisal of dichloromethotrexate". Journal of the National Cancer
Institute. 1988; 80: 1547 (#144393)
276.Rowinsky, E K; Donehower, R C; Jones, R J; Tucker, R W. "Microtubule changes and cytotoxicity in
leukemic cell lines treated with taxol". Cancer research. 1988; 48: 4093 (#144394)
277.Rowinsky, E K; Noe, D A; Orr, D W; Grochow, L B; Ettinger, D S; Donehower, R C. "Clinical pharmacology
of oral and i.v. N-methylformamide: a pharmacologic basis for lack of clinical antineoplastic activity".
Journal of the National Cancer Institute. 1988; 80: 671 (#144395)
278.Donehower, R C; Rowinsky, E K; Grochow, L B; Longnecker, S M; Ettinger, D S. "Phase I trial of taxol in
patients with advanced cancer". Cancer treatment reports. 1987; 71: 1171 (#144397)
279.Rowinsky, E K; Ettinger, D S; McGuire, W P; Noe, D A; Grochow, L B; Donehower, R C. "Prolonged infusion
of hexamethylene bisacetamide: a phase I and pharmacological study". Cancer research. 1987; 47: 5788
(#144398)
280.Rowinsky, E K; Harwood, K V; Ettinger, D S. "Sudden dyspnea occurring 24 hours after mitomycin plus
etoposide combination therapy". Cancer treatment reports. 1987; 71: 103 (#144400)
281.Rowinsky, E K; McGuire, W P; Anhalt, G J; Ettinger, D S; Donehower, R C. "Hexamethylene bisacetamideinduced cutaneous vasculitis". Cancer treatment reports. 1987; 71: 471 (#144399)
282.Rowinsky, E K; Ettinger, D S; Grochow, L B; Brundrett, R B; Cates, A E; Donehower, R C. "Phase I and
pharmacologic study of hexamethylene bisacetamide in patients with advanced cancer". Journal of clinical
oncology. 1986; 4: 1835 (#144401)
283.Rowinsky, E K; Jones, R J; Abeloff, M D. "Massive adrenal hemorrhage secondary to metastatic lung
carcinoma". Medical & pediatric oncology. 1986; 14: 234 (#144402)
284.Rowinsky, E K; Abeloff, M D; Wharam, M D. "Spontaneous pneumothorax following thoracic irradiation".
Chest. 1985; 88: 703 (#144403)
All data from NYU Health Sciences Library Faculty Bibliography
NYU Faculty may edit their publications and access other personalized services at http://myinfo.med.nyu.edu
or see: http://library.med.nyu.edu/library/eresources/faculty/bib-faq.html
Ethics
Disclaimer
Privacy Policy
Contact Webmaster
© 2011 Division of Hematology & Medical Oncology | Department of Medicine | 550 First Avenue, New York, NY 10016
Call us for more information:
212-2639015